Marriott International Inc vs Neurocrine Biosciences Inc — how do they compare? Marriott International Inc trades at $349.5 (market cap $90.86B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Marriott International Inc is far larger — about 5.4× Neurocrine Biosciences Inc's market cap, and Marriott International Inc pays a 0.84% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MAR | NBIX | |
|---|---|---|
Market Cap | $90.86B | $16.76B |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $185.50 |
52-Week Low | $259.04 | $123.10 |
Enterprise Value | $108.17B | $16.78B |
Dividend Yield | 0.84% | — |
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $353.91, down 1.6% in the last 24 hours, with a bearish technical signal. The stock shows strong profitability with a net income margin of 9.62% and ROE of 1,446.77%, but faces high valuation ratios like a P/E of 36.64. Recent Q2 2026 earnings beat estimates at $3.19 per share, and the company raised its 2026 outlook, though revenue missed expectations. A quarterly dividend of $0.73 per share was declared, payable on June 30, 2026.
The outlook is mixed: robust fee growth and a record pipeline support upside, but elevated debt and premium valuation pose risks. Analysts are generally positive with a consensus price target of $387.31, though near-term volatility may persist due to macroeconomic headwinds and regional weaknesses in the Middle East.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Trailing returns across standard periods
Latest headlines on both assets
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →